Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma

Yazmin Odia, Carl Koschmann, Nicholas A. Vitanza, Peter De Blank, Dolly Aguilera, Jeffrey Allen, Doured Daghistani, Matthew Hall, Ziad Khatib, Cassie Kline, Tobey Macdonald, Sabine Mueller, Shamia L. Faison, Joshua E. Allen, Odin J. Naderer, Samuel C. Ramage, Rohinton S. Tarapore, Susan Lynne McGovern, Soumen Khatua, Wafik ZakySharon L. Gardner

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Pages (from-to)S155-S164
JournalNeuro-Oncology
Volume26
Issue numberSupplement_2
DOIs
StatePublished - Apr 1 2024
Externally publishedYes

ASJC Scopus Subject Areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Keywords

  • dordaviprone
  • dose optimization
  • H3 K27M mutation
  • ONC201

Cite this